Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$9.34 USD

9.34
433,019

+0.14 (1.52%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $9.35 +0.01 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5% and 19.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates

by Ekta Bagri

We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.

Catalyst (CPRX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Revenues of Catalyst Pharmaceuticals (CPRX) are expected to have been driven by the sales of its only marketed product, Firdapse, for treating LEMS, along with the drug's label expansion for the treatment of pediatric patients.

Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Pharmaceuticals (IRWD) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -3.57% and 3.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris' (VTRS) Q4 results are likely to be impacted by foreign exchange rate fluctuations. With the Biocon deal closed, investors await its impact on the 2023 guidance.

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -26.47% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for February 14th

by Zacks Equity Research

INSP, ALK, SSKN, NVO and TBPH have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.

Why Is Theravance Bio (TBPH) Up 1.6% Since Last Earnings Report?

by Zacks Equity Research

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Theravance (TBPH) reports a narrower-than-expected loss for the third quarter of 2022. Revenues decline year over year.

Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of 4.55% and 34.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 48.94% and 1.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Sep 20, 2022

by Zacks Equity Research

Companies in The News Are: WIX,COIN,TBPH,GSK,MRNA

Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline

by Zacks Equity Research

Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of 33.33% and 36.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests

by Zacks Equity Research

Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva???s Trelegy royalty shares.

Is the Options Market Predicting a Spike in Theravance (TBPH) Stock?

by Zacks Equity Research

Investors need to pay close attention to Theravance (TBPH) stock based on the movements in the options market lately.

Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates

by Zacks Equity Research

Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.

Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of -100% and 20.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?